• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lyndra touts positive results for long-acting drug-delivery tech

November 15, 2018 By Sarah Faulkner

Lyndra updatedLyndra Therapeutics reported positive results from a pharmacokinetics study of its once-weekly drug-delivery capsule, touting that it successfully transitioned a once-daily therapy to a weekly dosage form.

The Watertown, Mass.-based company’s oral drug-delivery technique is designed to provide sustained release of one or more drugs for up to a week. Lyndra’s star-shaped capsule opens when it reaches the stomach and eventually leaves the body via the user’s gastrointestinal tract.

In an open-label, single dose PK study, eight healthy volunteers were treated with a prototype of the product containing memantine hydrochloride. The capsule’s PK profile and gastric-retentive properties were comparable to that of the commercially-available Namenda XR product.

All of the trial’s participants finished the study and tolerated the extended-release dosage form with transient, mild adverse events.

“As we set out to show with this study, preliminary data demonstrate predictable pharmacokinetics over seven days in healthy subjects,” co-founder & chief scientific officer Andrew Bellinger said in prepared remarks. “These positive results will accelerate our path toward commercialization, starting with our planned IND for schizophrenia in 2019 and targeting Phase II trials the following year.”

“Non-adherence to prescribed medications is a global epidemic, and this led us to start asking ‘what if we stopped trying to change people and changed the pill instead,'” CEO Amy Schulman added. “And that is exactly what we are working on—with these early positive results we can focus on making medicines that reduce the burden of the daily pill, starting with Alzheimer’s Disease and schizophrenia.”

In September last year, Lyndra landed a $105 million deal with Allergan (NYSE:AGN) to develop orally administered, once-weekly products for the treatment of Alzheimer’s disease.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: lyndra

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS